Table 5.

Severe nonhematologic toxicities in the IFM 95-01 trial analyzed by treatment allocation


Toxicity

Total, no. (%)

MP, no.

M-DEX, no.

DEX, no.

DEX-IFN, no.
Severe pyogenic infections   59 (12)   12   22   14   11  
   Pulmonary   25 (5)   5   11   5   4  
   Septicemia   18 (4)   2   5   6   5  
   Other   16 (3)   5   6   3   2  
Severe hemorrhage   10 (2)   2   3   5   0  
Perforated diverticulum   8 (2)   0   3   1   4  
Psychiatric complications   13 (2.5)   0   2   3   8* 
Severe diabetes   16 (3)   2   2   8   4  
DVT/pulmonary embolism   21 (4)   5   6   6   4  
Any severe toxicity
 
121 (25)
 
20
 
36
 
34
 
31
 

Toxicity

Total, no. (%)

MP, no.

M-DEX, no.

DEX, no.

DEX-IFN, no.
Severe pyogenic infections   59 (12)   12   22   14   11  
   Pulmonary   25 (5)   5   11   5   4  
   Septicemia   18 (4)   2   5   6   5  
   Other   16 (3)   5   6   3   2  
Severe hemorrhage   10 (2)   2   3   5   0  
Perforated diverticulum   8 (2)   0   3   1   4  
Psychiatric complications   13 (2.5)   0   2   3   8* 
Severe diabetes   16 (3)   2   2   8   4  
DVT/pulmonary embolism   21 (4)   5   6   6   4  
Any severe toxicity
 
121 (25)
 
20
 
36
 
34
 
31
 

The data were collected for 488 patients; for MP, n = 122; for M-DEX, n = 118; for DEX, n = 127; for DEX-IFN, n = 121.

DVT indicates deep venous thrombosis.

*

Including suicide in 1 patient

Close Modal

or Create an Account

Close Modal
Close Modal